Relevant Disclosure is attached.
Awaiting price reaction for this filing.
Fortis Healthcare's board, on May 20, 2025, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with statutory auditors (B S R & Co. LLP) issuing an unmodified opinion. For the full year FY25, standalone revenue from operations grew to about ₹1,445.9 crore (up from ~₹1,181.4 crore in FY24), but net profit fell sharply to ₹63.8 crore (vs ₹199.5 crore in FY24) mainly due to an exceptional loss of ₹115.1 crore from impairment of investments in subsidiary companies. Q4 FY25 standalone revenue was ₹388.5 crore, but the company posted a Q4 standalone net loss of ₹42.2 crore because of the impairment charge. The board also recommended a final dividend of ₹1 per share (10% on face value of ₹10), subject to shareholder approval, and appointed Neelam Gupta & Associates as secretarial auditor for 5 years (FY2025-30) and Jitender, Navneet & Co. as cost auditor for FY2025-26. Legal matters related to the ongoing SFIO investigation and the Fortis brand acquisition proceedings by the Delhi High Court continue as flagged by auditors.
The ₹1 final dividend is modest (around a 0.15-0.2% yield at recent share prices) and is unlikely to excite income-focused investors. The sharp FY25 profit fall — driven mostly by the one-time ₹115 crore investment impairment rather than weak operations — is a negative signal for headline earnings, though core operating EBITDA actually improved. Watch for the consolidated numbers and management commentary on the impairment for a clearer read on underlying business health.